LEADER 02293nmm a2200409 u 4500
001 EB001081507
003 EBX01000000000000000840914
005 00000000000000.0
007 cr|||||||||||||||||||||
008 151019 ||| eng
100 1 |a Deininger, Michael W. 
245 0 0 |a CML  |h Elektronische Ressource  |b genetic paradigm of targeted therapy, part 2 of 2  |c Michael W. Deininger 
246 3 1 |a genetic paradigm of targeted therapy. Part 2 
246 3 1 |a genetic paradigm of targeted therapy. Part 2 
260 |a London  |b Henry Stewart Talks  |c 2015, 2015 
300 |a 1 online resource (1 streaming video file (35 min.)  |b color, sound) 
505 0 |a Mechanisms of resistance to tyrosine kinase inhibitors (TKIs) -- Overcoming resistance with second and third generation TKIs -- Remaining difficulties in eradicating CML. 
653 |a Protein kinases / Inhibitors 
653 |a Protein Kinase Inhibitors / therapeutic use 
653 |a Protein-Tyrosine Kinases / antagonists & inhibitors 
653 |a Antineoplastic Agents / therapeutic use 
653 |a Drug Delivery Systems / methods 
653 |a imatinib 
653 |a Neoplasms / genetics 
653 |a Cancer / Genetic aspects 
653 |a Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy 
653 |a Drug delivery systems 
653 |a Antineoplastic agents 
653 |a Fusion Proteins, bcr-abl / antagonists & inhibitors 
653 |a Chronic myeloid leukemia 
041 0 7 |a eng  |2 ISO 639-2 
989 |b HST  |a Henry Stewart Talks 
490 0 |a Cancer genetics 
500 |a Animated audio-visual presentation with synchronized narration. - Title from title frames. - Mode of access: World Wide Web. - System requirements: Browser compatibility: updated Mozilla Firefox, Google Chrome, Safari or Internet Explorer 8+. Browser settings: enable JavaScript, enable cookies from the Henry Stewart Talks site. Required Desktop Browser plugins & viewers: Updated Adobe Flash Player & Adobe Acrobat Reader. Mobile device & operating system versions: Android v4.0+, iPhone 4+ (iOS v6.x+), iPad 2+ (iOS v6.x+), BlackBerry OS v7.0+, Windows Phone v6.5.1+ 
856 4 0 |u https://hstalks.com/bs/3132  |x Verlag  |z Streaming video file 
856 4 2 |u https://hstalks.com/bs/p/941  |3 Series 
082 0 |a 570